Global Dorzolamide Hydrochloride Market Research Report 2022
SKU ID :QYR-21590418 | Published Date: 31-Aug-2022 | No. of pages: 94Description
Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.
Due to the COVID-19 pandemic, the global Dorzolamide Hydrochloride market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Dorzolamide Hydrochloride market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Dorzolamide Hydrochloride landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
On-Line accounting for % of the Dorzolamide Hydrochloride global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pregnancy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Dorzolamide Hydrochloride include Alembic Pharms, Bausch and Lomb, FDC, Hi Tech Pharma, Micro Labs, Novartis, Merck and Purdue Pharma, etc. In terms of revenue, the global 3 largest players have a % market share of Dorzolamide Hydrochloride in 2021.
This report focuses on Dorzolamide Hydrochloride volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Dorzolamide Hydrochloride market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Dorzolamide Hydrochloride Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
On-Line
Hospital
Drug Store
Segment by Application
Pregnancy
Lactation
Pediatric Use
Geriatric Use
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Alembic Pharms
Bausch and Lomb
FDC
Hi Tech Pharma
Micro Labs
Novartis
Merck
Purdue Pharma
Due to the COVID-19 pandemic, the global Dorzolamide Hydrochloride market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Dorzolamide Hydrochloride market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Dorzolamide Hydrochloride landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
On-Line accounting for % of the Dorzolamide Hydrochloride global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pregnancy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Dorzolamide Hydrochloride include Alembic Pharms, Bausch and Lomb, FDC, Hi Tech Pharma, Micro Labs, Novartis, Merck and Purdue Pharma, etc. In terms of revenue, the global 3 largest players have a % market share of Dorzolamide Hydrochloride in 2021.
This report focuses on Dorzolamide Hydrochloride volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Dorzolamide Hydrochloride market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Dorzolamide Hydrochloride Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
On-Line
Hospital
Drug Store
Segment by Application
Pregnancy
Lactation
Pediatric Use
Geriatric Use
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Alembic Pharms
Bausch and Lomb
FDC
Hi Tech Pharma
Micro Labs
Novartis
Merck
Purdue Pharma
TOC
Tables & Figures
Companies
- PRICE
-
$2900$5800$4350Buy Now